{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-013457","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.966581+00:00","generated_at":"2026-06-26T21:44:48.843921+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed CFO Bruce Colwill retiring; Brenda Edwards named interim CFO","bullets":["Bruce Colwill steps down as CFO effective March 31, 2022; will remain advisor through June 30, 2022.","Brenda Edwards appointed interim CFO effective April 1, 2022; over 35 years of experience including 20+ years as CFO.","Company has initiated a search for a permanent CFO replacement.","Ms. Edwards engaged through a placement agency at CAD$210/hour."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-013457","json":"https://secwatch.observer/filing/0001213900-22-013457.json","markdown":"https://secwatch.observer/filing/0001213900-22-013457.md","text":"https://secwatch.observer/filing/0001213900-22-013457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022013457/0001213900-22-013457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022013457/ea157098-8k_inmedpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:44:48.843921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ba3f16427","claim":"Brenda Edwards was appointed as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"The Company appointed Ms. Brenda Edwards as Interim Chief Financial Officer of the Company effective April 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022013457/0001213900-22-013457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"cfeefb9382","claim":"Bruce Colwill retired as Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022013457/0001213900-22-013457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}